Vitura Health Limited (ASX: VIT)
Health Care · Pharmaceuticals · AU
AU$0.03
+4.17% today · -64.5% 1Y
Vitura Health Limited (ASX: VIT) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $11.88M and employs 72 people.
Over the last twelve months the share price has lost 64.5%, trading between 0.02 and 0.07.
Tweenvest scores Vitura Health Limited across four factors: quality 64/100, value 58/100, growth 100/100, dividend 91/100. Its strongest factor is growth.
VIT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.88M
- Revenue (TTM)
- $86.20M
- P/E
- 20.82
- EPS
- 0.00
- Dividend yield
- 8.00%
- Beta (5Y)
- -1.39
- 52-week high
- AU$0.07
- 52-week low
- AU$0.02
- Avg volume (3M)
- —
- Shares outstanding
- 662.74M
- Employees
- 72
- Next earnings
- —
About Vitura Health Limited
Established in 2018 and based in South Yarra, Australia, Vitura Health Limited focuses on the supply and marketing of medicinal cannabis goods throughout Australia and the Asian market. The company manages a portfolio of key brands, such as CanView, Burleigh Heads Cannabis, CDA Clinics, Cannadoc, and Adaya. This entity was formerly recognized as Cronos Australia Limited before adopting the name Vitura Health Limited in February 2023.
- ISIN
- AU0000266801
- Founded
- 2018
- Listed since
- Nov 6, 2019
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.80 | +0.11% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.72 | +0.51% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.